The general area of my lab’s research interest is in Cancer Immunology, in the context of brain (glioblastoma) and ovarian cancer. The remarkable success of cancer immunotherapies targetting T-cell checkpoint pathways suggest that cancers have evaded the immune system and blocking the evasion pathways can rearm the host's immune system to eradicate cancers. Unfortunately existing immunotherapies against T-cell checkpoint pathway do not work in the cancers of the brain and ovary. Existing studies suggest that tumour associated macrophages (TAMs) may be very high in these cancers and can be either excluding cytotoxic T cells from the tumour bed or turning them of either directly or through recruiting immunosuppresive cells such as regulatory T cells. In addition to contributing to immunosuppression in the tumour microenvironment, TAMs also appear to help tumour grow and metastasize through promoting blood vessel growth and matrix remodeling.  We combine both wet-lab genomic experiments and computational biology to generate and analyze single cell RNA-seq data on tumour infiltrating cells. We use computational analysis of single cell RNA-seq data to infer cell identity cells, their prevalence, to uncover the changes in their phenotypes relative to healthy tissues, the pro-tumour cytokine signaling within microenvironment in order to uncover mechanisms of immune evasion and mechanisms of therapy resistance mediated by the tumour microenvironment.  My lab is committed to making a significant clinical impact by discovering blood markers for early detection of cancer, by stratifying cancers based on immune phenotypes and uncovering biomarkers of response or resistance to immunotherapy.